361 Capital LLC acquired a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) in the third quarter, HoldingsChannel.com reports. The institutional investor acquired 49,772 shares of the biopharmaceutical company’s stock, valued at approximately $4,033,000. Gilead Sciences makes up approximately 0.8% of 361 Capital LLC’s holdings, making the stock its 24th largest holding.
Several other large investors have also recently bought and sold shares of the stock. Advisors Asset Management Inc. grew its holdings in shares of Gilead Sciences by 17.9% during the third quarter. Advisors Asset Management Inc. now owns 191,770 shares of the biopharmaceutical company’s stock worth $15,537,000 after buying an additional 29,118 shares in the last quarter. Commerce Bank grew its stake in Gilead Sciences by 3.3% in the third quarter. Commerce Bank now owns 53,816 shares of the biopharmaceutical company’s stock valued at $4,360,000 after purchasing an additional 1,722 shares in the last quarter. Welch Investments LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $108,000. Abbrea Capital LLC bought a new position in Gilead Sciences in the third quarter valued at approximately $215,000. Finally, Putnam FL Investment Management Co. bought a new position in Gilead Sciences in the third quarter valued at approximately $1,816,000. Institutional investors and hedge funds own 75.95% of the company’s stock.
A number of research analysts have weighed in on the company. Credit Suisse Group set a $80.00 price target on Gilead Sciences and gave the company a “hold” rating in a research note on Wednesday, January 3rd. Oppenheimer assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They issued a “market perform” rating for the company. Mizuho raised their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research note on Wednesday, November 8th. Leerink Swann raised their price target on Gilead Sciences from $87.00 to $89.00 and gave the company a “market perform” rating in a research note on Thursday, October 5th. Finally, BMO Capital Markets decreased their price target on Gilead Sciences from $89.00 to $83.00 and set an “outperform” rating for the company in a research note on Friday, October 27th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and eighteen have given a buy rating to the company’s stock. The company has a consensus rating of “Buy” and a consensus target price of $85.53.
In other news, EVP Gregg H. Alton sold 30,000 shares of Gilead Sciences stock in a transaction on Thursday, January 11th. The stock was sold at an average price of $79.00, for a total value of $2,370,000.00. Following the transaction, the executive vice president now owns 57,114 shares in the company, valued at approximately $4,512,006. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Gregg H. Alton sold 15,000 shares of Gilead Sciences stock in a transaction on Wednesday, November 1st. The shares were sold at an average price of $74.82, for a total value of $1,122,300.00. Following the completion of the transaction, the executive vice president now owns 77,363 shares in the company, valued at approximately $5,788,299.66. The disclosure for this sale can be found here. In the last quarter, insiders sold 491,666 shares of company stock worth $36,442,567. Corporate insiders own 1.30% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) opened at $81.74 on Thursday. The firm has a market capitalization of $106,750.00, a price-to-earnings ratio of 9.30, a price-to-earnings-growth ratio of -1.68 and a beta of 1.13. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. Gilead Sciences, Inc. has a fifty-two week low of $63.76 and a fifty-two week high of $86.27.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $2.13 by $0.14. The firm had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. The company’s quarterly revenue was down 13.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $2.75 EPS. equities research analysts anticipate that Gilead Sciences, Inc. will post 8.53 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 28th. Stockholders of record on Friday, December 15th were paid a $0.52 dividend. The ex-dividend date of this dividend was Thursday, December 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.54%. Gilead Sciences’s payout ratio is 23.66%.
Gilead Sciences Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.